Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10.

PMID:
24412048
2.

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Hérard AS, Day DM, Brouillet E, Kingsman SM, Hantraye P, Mitrophanous KA, Mazarakis ND, Palfi S.

Sci Transl Med. 2009 Oct 14;1(2):2ra4. doi: 10.1126/scitranslmed.3000130.

3.

Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.

Shingler WH, Chikoti P, Kingsman SM, Harrop R.

Int Immunol. 2008 Aug;20(8):1057-66. doi: 10.1093/intimm/dxn063. Epub 2008 Jun 20.

PMID:
18567615
4.

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE.

Cancer Immunol Immunother. 2008 Jul;57(7):977-86.

PMID:
18060404
5.

Analysis of factor VIII mediated suppression of lentiviral vector titres.

Radcliffe PA, Sion CJ, Wilkes FJ, Custard EJ, Beard GL, Kingsman SM, Mitrophanous KA.

Gene Ther. 2008 Feb;15(4):289-97. Epub 2007 Nov 29.

PMID:
18046428
6.

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4487-94.

7.

Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications.

Farley DC, Iqball S, Smith JC, Miskin JE, Kingsman SM, Mitrophanous KA.

J Gene Med. 2007 May;9(5):345-56.

PMID:
17366519
8.

The integration profile of EIAV-based vectors.

Hacker CV, Vink CA, Wardell TW, Lee S, Treasure P, Kingsman SM, Mitrophanous KA, Miskin JE.

Mol Ther. 2006 Oct;14(4):536-45.

9.

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.

Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3416-24.

10.

Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.

Wong LF, Goodhead L, Prat C, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Hum Gene Ther. 2006 Jan;17(1):1-9. Review. Erratum in: Hum Gene Ther. 2006 Mar;17(3):376.

PMID:
16409120
11.

Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord.

Wong LF, Yip PK, Battaglia A, Grist J, Corcoran J, Maden M, Azzouz M, Kingsman SM, Kingsman AJ, Mazarakis ND, McMahon SB.

Nat Neurosci. 2006 Feb;9(2):243-50. Epub 2005 Dec 25.

PMID:
16388307
12.

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.

Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW.

Cancer Immunol Immunother. 2006 Sep;55(9):1081-90. Epub 2005 Nov 26.

PMID:
16311730
13.

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.

Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M.

Nat Med. 2005 Apr;11(4):429-33. Epub 2005 Mar 13.

14.

Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, White L, Kan O, Naylor S, Carroll MW, Kingsman SM, Harris AL.

Clin Cancer Res. 2005 Feb 15;11(4):1512-20.

15.

Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.

Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, Wilkes F, Mitrophanous KA, Kingsman SM, Burghes AH, Mazarakis ND.

J Clin Invest. 2004 Dec;114(12):1726-31.

16.

Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus.

Wong LF, Ralph GS, Walmsley LE, Bienemann AS, Parham S, Kingsman SM, Uney JB, Mazarakis ND.

Mol Ther. 2005 Jan;11(1):89-95.

17.

Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE).

Kingsman SM, Mitrophanous K, Olsen JC.

Gene Ther. 2005 Jan;12(1):3-4. No abstract available.

PMID:
15510172
18.

Lentiviral vectors for treating and modeling human CNS disorders.

Azzouz M, Kingsman SM, Mazarakis ND.

J Gene Med. 2004 Sep;6(9):951-62. Review.

PMID:
15352068
19.

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND.

Nature. 2004 May 27;429(6990):413-7.

PMID:
15164063
20.

Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector.

Azzouz M, Ralph S, Wong LF, Day D, Askham Z, Barber RD, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Neuroreport. 2004 Apr 29;15(6):985-90.

PMID:
15076720
21.

Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia.

Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, White JR, Barber RD, Rayner W, Kingsman SM, Mundy CR, Mazarakis ND, Krige D.

J Cereb Blood Flow Metab. 2004 Feb;24(2):245-58.

PMID:
14747751
22.

Transduction patterns of pseudotyped lentiviral vectors in the nervous system.

Wong LF, Azzouz M, Walmsley LE, Askham Z, Wilkes FJ, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Mol Ther. 2004 Jan;9(1):101-11. Erratum in: Mol Ther. 2004 May;9(5):765.

23.

Lentivirus: a vector for nervous system applications.

Kingsman SM.

Ernst Schering Res Found Workshop. 2003;(43):179-207. Review. No abstract available.

PMID:
12894457
24.

Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice.

Waddington SN, Mitrophanous KA, Ellard FM, Buckley SM, Nivsarkar M, Lawrence L, Cook HT, Al-Allaf F, Bigger B, Kingsman SM, Coutelle C, Themis M.

Gene Ther. 2003 Aug;10(15):1234-40.

PMID:
12858188
25.

Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin.

Bienemann AS, Martin-Rendon E, Cosgrave AS, Glover CP, Wong LF, Kingsman SM, Mitrophanous KA, Mazarakis ND, Uney JB.

Mol Ther. 2003 May;7(5 Pt 1):588-96.

26.

Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.

Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM, Stern PL, Carroll MW.

Mol Cancer Ther. 2002 Oct;1(12):1129-37.

28.

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.

Myers KA, Ryan MG, Stern PL, Shaw DM, Embleton MJ, Kingsman SM, Carroll MW.

Cancer Gene Ther. 2002 Nov;9(11):884-96.

29.

Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro.

Corcoran J, So PL, Barber RD, Vincent KJ, Mazarakis ND, Mitrophanous KA, Kingsman SM, Maden M.

J Cell Sci. 2002 Oct 1;115(Pt 19):3779-86.

30.

Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors.

Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis ND, Kingsman SM.

Methods Enzymol. 2002;346:466-500. No abstract available.

PMID:
11883086
31.

Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA.

Hum Mol Genet. 2001 Sep 15;10(19):2109-21.

PMID:
11590128
32.

Use of intron-disrupted polyadenylation sites to enhance expression and safety of retroviral vectors.

Ismail SI, Rohll JB, Kingsman SM, Kingsman AJ, Uden M.

J Virol. 2001 Jan;75(1):199-204.

33.

Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.

Shaw DM, Embleton MJ, Westwater C, Ryan MG, Myers KA, Kingsman SM, Carroll MW, Stern PL.

Biochim Biophys Acta. 2000 Dec 15;1524(2-3):238-46.

PMID:
11113573
34.

Effects of stoichiometry of retroviral components on virus production.

Yap MW, Kingsman SM, Kingsman AJ.

J Gen Virol. 2000 Sep;81(Pt 9):2195-2202. doi: 10.1099/0022-1317-81-9-2195.

PMID:
10950977
35.

Characterization of the equine infectious anaemia virus S2 protein.

Yoon S, Kingsman SM, Kingsman AJ, Wilson SA, Mitrophanous KA.

J Gen Virol. 2000 Sep;81(Pt 9):2189-2194. doi: 10.1099/0022-1317-81-9-2189.

PMID:
10950976
36.

Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency.

Slingsby JH, Baban D, Sutton J, Esapa M, Price T, Kingsman SM, Kingsman AJ, Slade A.

Hum Gene Ther. 2000 Jul 1;11(10):1439-51.

PMID:
10910141
37.
38.

Possible regulatory function of the Saccharomyces cerevisiae Ty1 retrotransposon core protein.

Roth JF, Kingsman SM, Kingsman AJ, Martin-Rendon E.

Yeast. 2000 Jul;16(10):921-32.

39.

A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA.

J Virol. 2000 May;74(10):4839-52.

40.

Split-intron retroviral vectors: enhanced expression with improved safety.

Ismail SI, Kingsman SM, Kingsman AJ, Uden M.

J Virol. 2000 Mar;74(5):2365-71.

41.

Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix.

Wilson SA, Sieiro-Vazquez C, Edwards NJ, Iourin O, Byles ED, Kotsopoulou E, Adamson CS, Kingsman SM, Kingsman AJ, Martin-Rendon E.

Biochem J. 1999 Aug 15;342 ( Pt 1):97-103.

42.

TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I.

Wilson SA, Brown EC, Kingsman AJ, Kingsman SM.

Nucleic Acids Res. 1998 Aug 1;26(15):3460-7.

43.

Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ.

J Virol. 1998 Jan;72(1):811-6.

45.

Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17.

Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ, Kingsman SM, Kingsman AJ.

J Virol. 1997 May;71(5):3474-83.

46.

Functional dissection of the Moloney murine leukemia virus envelope protein gp70.

Bae Y, Kingsman SM, Kingsman AJ.

J Virol. 1997 Mar;71(3):2092-9.

47.

Identification of proteolytic cleavage sites within the gag-analogue protein of Ty1 virus-like particles.

Martin-Rendon E, Hurd DW, Marfany G, Kingsman SM, Kingsman AJ.

Mol Microbiol. 1996 Dec;22(5):1035-43.

PMID:
8971723
48.

Structural determinants within the subunit protein of Ty1 virus-like particles.

Martin-Rendon E, Marfany G, Wilson S, Ferguson DJ, Kingsman SM, Kingsman AJ.

Mol Microbiol. 1996 Nov;22(4):667-79.

PMID:
8951814
50.

The regulation of human immunodeficiency virus type-1 gene expression.

Kingsman SM, Kingsman AJ.

Eur J Biochem. 1996 Sep 15;240(3):491-507. Review.

Supplemental Content

Loading ...
Support Center